Market Closed -
Other stock markets
|
After market 12:20:17 pm | |||
1.295 EUR | -6.83% | 1.268 | -2.08% |
12:46pm | Medigene, BioNTech Extend Cancer Immunotherapy Partnership | MT |
May. 15 | Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS | CI |
Sales 2024 * | 10.6M 11.5M | Sales 2025 * | 6.95M 7.54M | Capitalization | 34.14M 37.05M |
---|---|---|---|---|---|
Net income 2024 * | -11M -11.94M | Net income 2025 * | -17M -18.45M | EV / Sales 2024 * | 4.82 x |
Net Debt 2024 * | 17M 18.45M | Net Debt 2025 * | 14M 15.19M | EV / Sales 2025 * | 6.93 x |
P/E ratio 2024 * |
-3.76
x | P/E ratio 2025 * |
-2.48
x | Employees | 76 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.05% |
Latest transcript on Medigene AG
1 day | -6.12% | ||
1 week | -13.09% | ||
Current month | -6.16% | ||
1 month | -32.55% | ||
3 months | -15.64% | ||
6 months | -22.22% | ||
Current year | -15.08% |
Managers | Title | Age | Since |
---|---|---|---|
Selwyn Ho
CEO | Chief Executive Officer | 53 | 22-07-24 |
Dolores Schendel
CTO | Chief Tech/Sci/R&D Officer | - | 14-04-30 |
Pamela Keck
IRC | Investor Relations Contact | - | 23-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 16-08-11 | |
Frank Mathias
BRD | Director/Board Member | 62 | 18-05-14 |
Anthony Man
BRD | Director/Board Member | 68 | 20-12-15 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-21 | 1.295 | -6.83% | 184 379 |
24-05-20 | 1.39 | -1.07% | 62,150 |
24-05-17 | 1.405 | -0.71% | 20,249 |
24-05-16 | 1.415 | -5.35% | 42,225 |
24-05-15 | 1.495 | +0.34% | 2,641 |
Delayed Quote Xetra, May 21, 2024 at 11:36 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.08% | 37.08M | |
+8.16% | 115B | |
+13.00% | 107B | |
-13.60% | 22.31B | |
-3.99% | 21.6B | |
-5.51% | 18.23B | |
-39.93% | 17.62B | |
+7.37% | 14.26B | |
+33.66% | 12.37B | |
-28.45% | 8.28B |
- Stock Market
- Equities
- MDG1 Stock